Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia

Kamae, Isao
October 2010
PharmacoEconomics;2010, Vol. 28 Issue 10, p831
Academic Journal
Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st century. Whilst Japan has seen very limited use of health technology assessment (HTA), South Korea, Taiwan and Thailand have had remarkable success in establishing government agencies for HTA, employing HTA concepts from the UK National Institute for Health and Clinical Excellence (NICE). These three countries are driven by the following common factors: (i) a desire to establish universal healthcare insurance coverage in their respective nations; (ii) the need for rational allocation of scarce resources; (iii) a desire for government to provide leadership in HTA; and (iv) availability of HTA professionals and faculties through international networks. The HTA models introduced by these three countries are both similar to and different from those of HTA agencies in Europe, but might work well as examples for other countries in the region.


Related Articles

  • UK NICE far from perfect, says health economist.  // PharmacoEconomics & Outcomes News;12/2/2006, Issue 517, p2 

    A reprint of the article "Economic Evaluation and Decision Making in the UK," by Martin J. Buxton in a 2006 issue of "PharmacoEconomics" is presented. It contends that there are significant problems in the decision-making process of Great Britain's National Institute for Health and Clinical...

  • NICE considers the patient.  // PharmacoEconomics & Outcomes News;2/21/2009, Issue 572, p3 

    The article reports on a study by the British National Institute for Health & Clinical Excellence (NICE), investigating how value, to patients, is explored when new health technologies are considered, and new guidance on engaging patients in decision surrounding prescribed medicines. The...

  • Economic evaluation of healthcare technologies using primary research.  // Evidence Based Nursing;Jul2008, Vol. 11 Issue 3, p67 

    The article discusses the need for British clinicians and policy makers to have a clear understanding of the significance of economic evaluations of health technologies. National clinical guidelines and technology assessments to direct practice are produced by the National Institute of Health...

  • Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Spinner, Daryl S.; Birt, Julie; Walter, Jeffrey W.; Bowman, Lee; Mauskopf, Josephine; Drummond, Michael F.; Copley-Merriman, Catherine // ClinicoEconomics & Outcomes Research;2013, Vol. 5, p69 

    Background: Health-technology assessment (HTA) plays an important role in informing drug-reimbursement decision-making in many countries. HTA processes for the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, the Common Drug Review (CDR) in Canada, and the National Institute for...

  • Reimbursement Decisions of the All Wales Medicines Strategy Group Influence of Policy and Clinical and Economic Factors. Linley, Warren G.; Hughes, Dyfrig A. // PharmacoEconomics;2012, Vol. 30 Issue 9, p779 

    Background: There have been several explorations of factors influencing the reimbursement decisions of the National Institute for Health and Clinical Excellence (NICE) but not of other UK-based health technology assessment (HTA) organizations. Objective: This study aimed to explore the factors...

  • NICE: alone in Europe but not the world. Gillies, Malcolm B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/21/2009, p429 

    No abstract available.

  • NICE result for Exogen and Watch BP Home A.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p11 

    The article reports that a medical technology guidance supporting the Exogen ultrasound bone healing system and the WatchBP Home A device has been published by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.

  • Proposed amendments to NICE's HTA methods criticised.  // PharmacoEconomics & Outcomes News;Oct2014, Vol. 713 Issue 1, p8 

    The article reports on commentaries published in the journal "PharmacoEconomics," which include one by Mike Paulden from University of Alberta, Edmonton, on NICE's previous amendments to its methods for health technology appraisal (HTA) and another by Suzanne R. Hill and Leslie G. Olson from...

  • Who values evidence? Littlejohns, Peter // Journal of Neurology, Neurosurgery & Psychiatry;Feb2014, Vol. 85 Issue 2, p123 

    The article presents the author's views regarding Australian researcher Roy Moynihan's work on the factors responsible for better future prospect of healthcare. Topics discussed include technological interventions in healthcare, healthcare guidelines proposed by Great Britain's National...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics